Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2023-01-27 Devyser Diagnostics Devyser Diagnostics AB: Devyser makes provisions due to retroactive "payback" levy Pressreleaser Visa Stäng
2023-01-27 Devyser Diagnostics Devyser Diagnostics AB: Devyser gör reservering på grund av retroaktiv "payback"-avgift Pressreleaser Visa Stäng
2022-12-02 Penser Access Penser Access: Lockande läge inför 2023 - Devyser Analyser Visa Stäng
2022-11-15 Analysguiden Analysguiden: ANALYS Devyser: Stabilt kvartal och många pusselbitar faller på plats Analyser Ladda ner | Visa Stäng
2022-11-15 Penser Access Penser Access: Intervju med Devyser - Erik Penser Bank - 15 nov 2022 Analyser Visa Stäng
2022-11-11 Redeye Redeye: Devyser Q3 - Solid performance and strong gross margin Analyser Ladda ner | Visa Stäng
2022-11-10 Pinpoint Estimates Pinpoint Estimates: Devyser Diagnostics rapport i linje med Pinpointkonsensus Analyser Ladda ner | Visa Stäng
2022-11-10 Devyser Diagnostics Devyser Diagnostics AB publishes Interim Report for the period, January to September 2022 Rapporter Ladda ner | Visa Stäng
Rapporter | 10 Nov 2022 | Devyser

Devyser Diagnostics AB publishes Interim Report for the period, January to September 2022

”Devyser reports yet another quarter of record sales and strong gross margins. The positive sales and margin trend remains stable.

We are following the strategic plan we launched nearly two years ago. It involves converting to direct sales in certain markets where we are currently working with distributors, and increasing our focus on selected key markets, including the important North American market. So far, we have managed to exceed the plan’s high expectations on sales growth and margins.”

Fredrik Alpsten, CEO, Devyser

Quarter July-September 2022

  • Net sales amounted to SEK 31.2 million (24.3), corresponding to a 28.1% increase. Adjusted for exchange rate fluctuations, net sales increased by 22.2%.
  • Gross profit totaled SEK 26.3 million (19.1), corresponding to a gross margin of 84.4% (78.5).
  • Operating profit (EBIT) amounted to SEK -8.2 million (-2.5).
  • Profit after tax totaled SEK -8.8 million (-3.6).
  • Earnings per share before and after dilution amounted to SEK -0.55 (-0.32).
  • Cash flow from operating activities stood at SEK -11.8 million (-3.2).

The period from January to September 2022

  • Net sales amounted to SEK 92.4 million (69.0), corresponding to a 34.0% increase. Adjusted for exchange rate fluctuations, net sales increased by 28.8%.
  • Gross profit totaled SEK 76.2 million (53.5), corresponding to a gross margin of 82.5% (77.5).
  • Operating profit (EBIT) amounted to SEK -26.0 million (-7.3).
  • Profit after tax totaled SEK -29.3 million (-10.1).
  • Earnings per share before and after dilution amounted to SEK -1.84 (-0.92).
  • Cash flow from operating activities stood at SEK -27.1 million (-10.6).

Important events during the quarter

Certification under the new European IVD Regulation

In August, Devyser was certified under the new, more comprehensive IVD Regulation, which came into force on May 26, 2022. The regulation ensures the highest level of clinical safety for the manufacture of medical devices. The certification covers Devyser’s quality management system and fetal diagnostics product.

Strengthening of the management team

In September, Camilla Wiberg took up the position of CHRO (Chief Human Resources Officer). Following Camilla Wiberg’s appointment, Devyser’s senior management consists of CEO Fredrik Alpsten, CFO Sabina Berlin, CCO Theis Kipling, COO Göran Rydin, CHRO Camilla Wiberg and Deputy CEO Ulf Klangby.

New share issues

In July, 63,900 shares were issued in connection with the exercising of warrants. The new issue raised SEK 0.8 million for the company. Following the issue, the number of Devyser shares totaled 16,006,369.

Important events after the end of the quarter

Establishes CLIA lab in USA

Adding to the company’s current business model, Devyser will establish a CLIA laboratory in Atlanta, Georgia, USA. CLIA, Clinical Laboratory Improvement Amendments, is an opportunity that enables Devyser to offer test services directly to its US customers. The company aims to have the lab CLIA-certified and operational in the second quarter 2023.

The report is available on the company’s webpage:  https://investors.devyser.com/en/reports-presentations

This information is information that Devyser Diagnostics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact persons below, on November 10, 2022 at 07:30 CET.

For more information, please contact:

Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46706 673 106

Sabina Berlin, CFO
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519502

About Devyser Diagnostics AB (publ)

Devyser develops, produces, and commercializes genetic test kits for laboratories in more than 45 countries. The products are used for advanced DNA testing within hereditary diseases, oncology, and transplantation to guide targeted cancer therapies, diagnose a wide array of genetic diseases, and to assist in post-transplant follow-up. Devyser’s products simplify complex genetic testing processes, minimize hands-on time and deliver rapid, accurate, and trusted results. Devyser was founded in 2004 and is based in Stockholm, Sweden.

Devyser’s shares are listed on Nasdaq First North Growth Market (ticker: DVYSR).The company’s Certified Adviser is Redeye AB. For more information, visit www.devyser.com.

2022-11-10 Devyser Diagnostics Devyser Diagnostics AB publicerar delårsrapport för januari till september 2022 Rapporter Ladda ner | Visa Stäng
2022-11-09 Devyser Diagnostics Devyser Diagnostics AB: Devyser strengthens its presence on the US market - establishes proprietary CLIA lab Pressreleaser Visa Stäng
2022-11-09 Devyser Diagnostics Devyser Diagnostics AB: Devyser stärker sin närvaro i USA - öppnar eget CLIA-laboratorium Pressreleaser Visa Stäng
2022-11-08 Penser Access Penser Access: Tillväxt i sitt DNA - Devyser Analyser Visa Stäng
2022-11-02 Devyser Diagnostics Devyser Diagnostics AB: Inbjudan till audiocast för Devysers Q3-rapport 2022 Pressreleaser Visa Stäng
2022-11-02 Devyser Diagnostics Devyser Diagnostics AB: Invitation to audiocast for Devyser's Q3 Report 2022 Pressreleaser Visa Stäng
2022-11-01 Devyser Diagnostics Devyser Diagnostics AB: Devyser appoints John Murad as General Manager in the US Pressreleaser Visa Stäng
2022-11-01 Devyser Diagnostics Devyser Diagnostics AB: Devyser utser John Murad till General Manager i USA Pressreleaser Visa Stäng
2022-10-31 Devyser Diagnostics Devyser Diagnostics AB: Devyser appoints Carnegie Investment Bank AB as liquidity provider Pressreleaser Visa Stäng
2022-10-31 Devyser Diagnostics Devyser Diagnostics AB: Devyser utser Carnegie Investment Bank till likviditetsgarant Pressreleaser Visa Stäng
2022-08-29 Devyser Diagnostics Devyser Diagnostics AB: Devysers kvalitetsledningssystem och produkt för fosterdiagnostik godkända enligt nya europeiska IVDR-regelverket Pressreleaser Ladda ner | Visa Stäng
2022-08-29 Devyser Diagnostics Devyser Diagnostics AB: Devyser's quality management system and fetal diagnostics product approved under the new European IVD Regulation Pressreleaser Ladda ner | Visa Stäng
2022-08-29 Redeye Redeye: Devyser Q2 - Delivering well on its financial targets Analyser Ladda ner | Visa Stäng
2022-08-26 Analysguiden Analysguiden: ANALYS Devyser Diagnostics: Stark tillväxt och vinner viktig mark i Kanada Analyser Ladda ner | Visa Stäng
2022-08-24 Pinpoint Estimates Pinpoint Estimates: Devyser Diagnostics nettoomsättning strax under Pinpointkonsensus Analyser Ladda ner | Visa Stäng
2022-08-24 Devyser Diagnostics Devyser Diagnostics AB publicerar delårsrapport för januari till juni 2022 Rapporter Ladda ner | Visa Stäng
2022-08-24 Devyser Diagnostics Devyser Diagnostics AB publishes Interim Report for the period, January to June 2022 Rapporter Ladda ner | Visa Stäng
2022-08-18 Devyser Diagnostics Devyser Diagnostics AB: Devyser appoints Camilla Wiberg as Chief HR Officer Pressreleaser Visa Stäng
2022-08-18 Devyser Diagnostics Devyser Diagnostics AB: Devyser utser Camilla Wiberg till Chief HR Officer Pressreleaser Visa Stäng
2022-08-17 Pinpoint Estimates Pinpoint Estimates: Devyser Diagnostics inleder samarbete med estimattjänsten Pinpoint Estimates Analyser Ladda ner | Visa Stäng
2022-08-17 Devyser Diagnostics Devyser Diagnostics AB: Inbjudan till audiocast för Devysers Q2-rapport 2022 Pressreleaser Visa Stäng
2022-08-17 Devyser Diagnostics Devyser Diagnostics AB: Invitation to audiocast for Devyser's Q2 Report 2022 Pressreleaser Visa Stäng
2022-06-22 Devyser Diagnostics Devyser Diagnostics AB: Devyser wins breakthrough contract in Canada for non-invasive fetal RHD testing Pressreleaser Ladda ner | Visa Stäng
2022-06-22 Devyser Diagnostics Devyser Diagnostics AB: Devyser vinner genombrottskontrakt i Kanada för icke-invasiv RHD-testning av foster Pressreleaser Ladda ner | Visa Stäng
2022-06-07 Analysguiden Analysguiden: INITIERINGSANALYS DEVYSER DIAGNOSTICS: Snabbväxare inom gentest med skyhöga marginaler Analyser Ladda ner | Visa Stäng
2022-05-12 Redeye Redeye: Devyser - A Strong Start to 2022 Analyser Ladda ner | Visa Stäng
2022-05-11 Devyser Diagnostics Kommuniké från årsstämma i Devyser Diagnostics AB (publ) den 11 maj 2022 Pressreleaser Ladda ner | Visa Stäng
2022-05-11 Devyser Diagnostics Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 11 May 2022 Pressreleaser Ladda ner | Visa Stäng
2022-05-11 Devyser Diagnostics Devyser Diagnostics AB: Record sales and increased gross margin for Devyser Rapporter Ladda ner | Visa Stäng
2022-05-11 Devyser Diagnostics Devyser Diagnostics AB: Rekordförsäljning och ökad bruttomarginal för Devyser Rapporter Ladda ner | Visa Stäng
2022-05-10 Devyser Diagnostics Devyser Diagnostics AB: Devyser presenterar på Aktiedagen Göteborg den 16 maj Pressreleaser Visa Stäng
2022-05-02 Devyser Diagnostics Devyser Diagnostics AB: Inbjudan till audiocast för Devysers Q1-rapport 2022 Pressreleaser Visa Stäng
2022-05-02 Devyser Diagnostics Devyser Diagnostics AB: Invitation to audiocast for Devyser's Q1 Report 2022 Pressreleaser Visa Stäng
2022-04-13 Devyser Diagnostics Kallelse till årsstämma 2022 i Devyser Diagnostics AB Pressreleaser Ladda ner | Visa Stäng
2022-04-12 Devyser Diagnostics Devyser Diagnostics AB: Devyser ökar kommersiellt fokus genom nyrekrytering till ledningsgruppen Pressreleaser Ladda ner | Visa Stäng
2022-04-12 Devyser Diagnostics Devyser Diagnostics AB: New appointment to Devyser's management team enhances commercial focus Pressreleaser Ladda ner | Visa Stäng
2022-04-06 Devyser Diagnostics Devyser Diagnostics AB: Devyser publishes annual report for 2021 Rapporter Ladda ner | Visa Stäng
2022-04-06 Devyser Diagnostics Devyser Diagnostics AB: Devyser publicerar årsredovisning för 2021 Rapporter Ladda ner | Visa Stäng
2022-04-06 Redeye Redeye: Redeye Initiates Coverage of Devyser Analyser Ladda ner | Visa Stäng

Kommande händelser

21 Feb 2023 | Bokslutskommuniké 2022
9 May 2023 | Kvartalsrapport 2023-Q1
10 May 2023 | Årsstämma 2022
23 Aug 2023 | Kvartalsrapport 2023-Q2
9 Nov 2023 | Kvartalsrapport 2023-Q3